Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-40632
Titel: Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30-year SIOP-RTSG experience
VerfasserIn: Hol, Janna A.
Jongmans, Marjolijn C. J.
Sudour-Bonnange, Hélène
Ramírez-Villar, Gema L.
Chowdhury, Tanzina
Rechnitzer, Catherine
Pal, Niklas
Schleiermacher, Gudrun
Karow, Axel
Kuiper, Roland P.
de Camargo, Beatriz
Avcin, Simona
Redzic, Danka
Wachtel, Antonio
Segers, Heidi
Vujanic, Gordan M.
van Tinteren, Harm
Bergeron, Christophe
Pritchard-Jones, Kathy
Graf, Norbert
van den Heuvel-Eibrink, Marry M.
Sprache: Englisch
Titel: Cancer
Bandnummer: 127 (2021)
Heft: 4
Seiten: 628-638
Verlag/Plattform: Wiley
Erscheinungsjahr: 2020
Freie Schlagwörter: aniridia
pediatric
predisposition
surveillance
treatment
WAGR syndrome (Wilms tumor, aniridia, genitourinary anomalies, and range of developmental delays)
Wilms tumor
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: BACKGROUND: WAGR syndrome (Wilms tumor, aniridia, genitourinary anomalies, and range of developmental delays) is a rare contiguous gene deletion syndrome with a 45% to 60% risk of developing Wilms tumor (WT). Currently, surveillance and treatment recommendations are based on limited evidence. METHODS: Clinical characteristics, treatments, and outcomes were analyzed for patients with WAGR and WT/nephroblastomatosis who were identified through International Society of Pediatric Oncology Renal Tumor Study Group (SIOP-RTSG) registries and the SIOP-RTSG network (1989-2019). Events were defined as relapse, metachronous tumors, or death. RESULTS: Forty-three patients were identified. The median age at WT/nephroblastomatosis diagnosis was 22 months (range, 6-44 months). The overall stage was available for 40 patients, including 15 (37.5%) with bilateral disease and none with metastatic disease. Histology was available for 42 patients; 6 nephroblastomatosis without further WT and 36 WT, including 19 stromal WT (52.8%), 12 mixed WT (33.3%), 1 regressive WT (2.8%) and 2 other/indeterminable WT (5.6%). Blastemal type WT occurred in 2 patients (5.6%) after prolonged treatment for nephroblastomatosis; anaplasia was not reported. Nephrogenic rests were present in 78.9%. Among patients with WT, the 5-year event-free survival rate was 84.3% (95% confidence interval, 72.4%-98.1%), and the overall survival rate was 91.2% (95% confidence interval, 82.1%-100%). Events (n = 6) did not include relapse, but contralateral tumor development (n = 3) occurred up to 7 years after the initial diagnosis, and 3 deaths were related to hepatotoxicity (n = 2) and obstructive ileus (n = 1). CONCLUSIONS: Patients with WAGR have a high rate of bilateral disease and no metastatic or anaplastic tumors. Although they can be treated according to existing WT protocols, intensive monitoring of toxicity and surveillance of the remaining kidney(s) are advised. Cancer 2021;127:628- 638. © 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. LAY SUMMARY: • WAGR syndrome (Wilms tumor, aniridia, genitourinary anomalies, and range of developmental delays) is a rare genetic condition with an increased risk of developing Wilms tumor. • In this study, 43 patients with WAGR and Wilms tumor (or Wilms tumor precursor lesions/nephroblastomatosis) were identified through the international registry of the International Society of Pediatric Oncology Renal Tumor Study Group (SIOP-RTSG) and the SIOP-RTSG network. In many patients (37.5%), both kidneys were affected. Disease spread to other organs (metastases) did not occur. • Overall, this study demonstrates that patients with WAGR syndrome and Wilms tumor can be treated according to existing protocols. However, intensive monitoring of treatment complications and surveillance of the remaining kidney(s) are advised.
DOI der Erstveröffentlichung: 10.1002/cncr.33304
URL der Erstveröffentlichung: https://doi.org/10.1002/cncr.33304
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-406328
hdl:20.500.11880/36504
http://dx.doi.org/10.22028/D291-40632
ISSN: 1097-0142
0008-543X
Datum des Eintrags: 28-Sep-2023
Bezeichnung des in Beziehung stehenden Objekts: Supporting Information
In Beziehung stehendes Objekt: https://acsjournals.onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fcncr.33304&file=cncr33304-sup-0001-Supinfo.pdf
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Pädiatrie
Professur: M - Prof. Dr. Norbert Graf
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
Cancer - 2020 - Hol.pdf202,63 kBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons